Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.
/ 913 items
#Healthcare↓
IDEAYA Gets FDA Green Light for Groundbreaking Cancer Treatment
IDEAYA Biosciences receives FDA clearance for IDE034, a first-in-class dual-target cancer therapy aimed at lung, colorectal, and head and neck tumors.
First Stargardt Disease Treatment Shows 36% Lesion Reduction
Belite Bio's tinlarebant demonstrates first successful Phase 3 results for Stargardt disease, reducing retinal lesion growth by 36% in adolescent patients.
INVO Fertility Expands Midwest Presence with Family Beginnings Acquisition
INVO Fertility announces planned acquisition of Indiana's Family Beginnings clinic, marking its second acquisition and expanding its nationwide fertility care network across the Midwest.
Vanda's Motion Sickness Drug Faces More Delays
Vanda Pharmaceuticals' (VNDA) tradipitant approval delayed again as FDA extends clinical hold review while labeling issues emerge for the motion sickness treatment.
HeartBeam Pursues Multiple Paths After FDA Setback
HeartBeam responds to FDA's NSE decision on its 12-lead ECG software with appeal plans and labeling modifications to advance heart monitoring technology.